Systemic lupus erythematosus flares during pregnancy

Area of Science:

• Rheumatology
• Obstetrics
• Endocrinology

Background:

• Pregnancy is a period of significant hormonal changes.
• Systemic lupus erythematosus (SLE) activity is a concern during pregnancy.
• Recent research highlights the interplay between sex hormones and SLE.

Purpose of the Study:

• To review current understanding of lupus activity during pregnancy.
• To discuss diagnostic challenges of SLE flares in pregnant patients.
• To evaluate treatment strategies for SLE during gestation.

Main Methods:

• Review of recent scientific literature on SLE and pregnancy.
• Analysis of clinical and laboratory data for SLE flare diagnosis.
• Assessment of the safety and efficacy of various SLE medications in pregnancy.

Main Results:

• SLE activity frequently increases during pregnancy, with flares often mild and affecting skin/joints.
• Kidney involvement is the primary factor conferring adverse pregnancy prognosis.
• Sex hormones, particularly prolactin, may contribute to increased SLE activity.
• Prophylactic corticosteroids (prednisone) are not supported by data for routine use.
• Hydroxychloroquine (HCQ) is considered safe for the fetus.

Conclusions:

• SLE flares during pregnancy require careful clinical and laboratory assessment for diagnosis.
• Treatment decisions for SLE flares should be individualized based on severity.
• Medications like NSAIDs, HCQ, prednisone, and azathioprine can be used for treatment.
• HCQ is a safe option for managing SLE during pregnancy.